Resilience in people with opioid use disorder
Official title: A Novel Human Laboratory Model of Resilience Among Individuals With Opioid Use Disorder
Run by Johns Hopkins University · NCT06954402 · Data updated 2026-11-12
This project will test whether short lab tasks performed during stress and non‑stress sessions match up with self‑rated resilience in adults with opioid use disorder.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 125 (estimated) |
| Sponsor | Johns Hopkins University Academic / other |
| Locations | 2 sites (Baltimore, Maryland and 1 other locations) |
| Status | Recruiting |
| Started | May 29, 2026 |
| Main results expected | April 30, 2029 |
| Study ends | April 30, 2029 |
| Registry record updated | June 23, 2026 |
| Trial ID | NCT06954402 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) who meet DSM‑5 criteria for current opioid use disorder or are receiving OUD pharmacotherapy, can give informed consent, and have a urine test positive for opioids are ideal candidates.
✕Probably not a fit
People who are pregnant or breastfeeding, have unstable serious psychiatric or medical conditions that interfere with participation, or are not currently using opioids are unlikely to gain benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This outpatient, within‑subject randomized study has participants complete two experimental sessions in random order: one using an acute stress induction and one using a non‑stress control. In each session participants perform standardized tasks designed to probe cognitive, emotional, and control aspects of resilience while researchers collect task performance, physiological measures, and self‑reported stress responses. The goal is to develop and validate a laboratory model that links objective behaviors and physiology to subjective resilience in people with OUD. Sessions occur at a single clinical site and use established stress paradigms adapted for this population.
Why it matters
Potential benefit: If successful, the approach could provide objective measures of resilience that help identify who is at higher risk of stress‑related relapse and guide tailored interventions.
How similar studies have gone: Related laboratory stress paradigms have been used successfully in addiction and psychiatric research to link stress reactivity to clinical outcomes, but applying them specifically to model resilience in OUD is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Can provide informed consent and can comply with study procedures 2. Adults aged ≥18 years 3. Meet Diagnostic and Statistical Manual (DSM-5) criteria for current opioid use disorder or are currently receiving pharmacotherapy for the treatment of OUD (e.g. methadone or buprenorphine maintenance treatment \[remission\]) 4. Urine sample that tests positive for opioids 5. Test negative for pregnancy at screening (females only) Exclusion Criteria: 1. Being pregnant or breastfeeding 2. Significant mental health or physical disorder, or life circumstances, that is judged by the investigators to interfere with study participation
Where it's running
-
Johns Hopkins University Bayview Medical Campus
Baltimore, Maryland, United States Recruiting -
Johns Hopkins University Bayview Medical Campus
Baltimore, Maryland, United States Not yet recruiting
Study contacts
- Principal investigator: Suky Martinez, PhD — Johns Hopkins University
- Study coordinator: Suky Martinez, PhD
- Email: smart209@jh.edu
- Phone: 410-550-0007
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CBD for Opioid Dependence and Pain on Buprenorphine
This study tests whether different doses of cannabidiol (CBD) can affect pain and opioid cravings in adults with opioid use disorder who are on buprenorphine, using a short, randomized, placebo-controlled setup.
-
Cebranopadol for opioid withdrawal in adults with chronic pain
This study tests whether cebranopadol can reduce withdrawal symptoms in adults with chronic pain who are physically dependent on prescribed opioids, compared with placebo.
-
emPath platform pilot to link and keep adults with opioid use disorder in care in Durham
This pilot tests a mobile app and telemedicine approach to help adults with opioid use disorder start and stay in MOUD through community outreach in Durham, NC.
-
CB1 Receptors in Opioid Use Disorder Measured with a PET Radioligand
This study tests CB1 receptor availability in people with opioid use disorder starting opioid agonist therapy and compares them with healthy adults.
-
STORC: Training a support person plus patient navigation after birth
We’re testing whether training a designated support person and using patient navigation after delivery helps people with opioid use disorder build recovery resources and stay in treatment.
-
Personalized Addiction Treatment Enhancement for Opioid Use Disorder
A digital platform run by peer recovery supporters will be tested to help adults with opioid use disorder who are on buprenorphine or methadone stay in treatment and improve outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.